API

As a novel potassium-competitive acid blocker, VONOZOPRAN FUMARATE may provide reversible acid suppression by preventing K+ from binding to gastric H+/K+-ATPase. It has been clinically used for the short-term treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease and Helicobacter pylori (H. pylori) infection.

Products still subject to third-party patent protection might be available solely for R&D purposes.

TENOXICAM is a nonsteroidal anti-inflammatory drug (NSAID). It is used to relieve inflammation, swelling, stiffness and pain.

Products still subject to third-party patent protection might be available solely for R&D purposes.

LIDAMIDINE HCL is an antidiarrheal agent that has potent antimotility, antidiarrheal and antisecretory activity.

Products still subject to third-party patent protection might be available solely for R&D purposes.

PRANLUKAST HYDRATE is a cysteinyl leukotriene receptor-1 antagonist. It is widely used in Japan.

Products still subject to third-party patent protection might be available solely for R&D purposes.